ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
ProKidney Corp (Nasdaq: PROK), a late clinical-stage biotech company specializing in cell therapy for chronic kidney disease (CKD), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bruce Culleton, M.D., will deliver a presentation on January 15, 2025, at 7:30am PST.
The company's management team will be available for one-on-one meetings during the event. Interested parties can access the live webcast through the 'Events' section of ProKidney's Investor Relations webpage at www.prokidney.com. A replay of the presentation will remain available for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PROK gained 1.10%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.
| 43rd Annual J.P. Morgan Healthcare Conference | |
| Date: | January 15, 2025 |
| Time: | 7:30am PST |
| Format: | Presentation |
| Webcast: | Link |
The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the event, a replay will be available for 90 days.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will ProKidney's (PROK) J.P. Morgan Conference presentation replay be available?
Where can investors watch ProKidney's (PROK) J.P. Morgan Healthcare Conference presentation?
What is ProKidney's (PROK) main focus in development?
Will ProKidney (PROK) management be available for individual meetings at the J.P. Morgan Conference?
